Mytide Therapeutics
Mytide's automated peptide manufacturing technology accelerates the discovery and development of peptide therapeutics.
Mytide's automated peptide manufacturing technology accelerates the discovery and development of peptide therapeutics.
Mytide Therapeutics, a groundbreaking technology startup based in the United States, is revolutionizing the field of biotechnology and healthcare. With the slogan "Mytide's automated peptide manufacturing technology accelerates the discovery and development of peptide therapeutics," the company aims to expedite the process of creating life-saving therapies. Founded in 2018, Mytide's innovative approach to automated peptide manufacturing, predictive analytics, and machine learning has garnered significant attention. The company recently secured a $7.00M Series A investment on 08 March 2022 from prominent investors including Trog Hawley Capital, Uncommon Denominator, and Alloy Therapeutics. Mytide's focus on fast and cost-efficient manufacturing of peptide therapeutics positions it as a promising player in the biotechnology and healthcare industries. The combination of cutting-edge technology and strategic investments sets the stage for Mytide Therapeutics to continue making a profound impact on the development of life-saving treatments.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $7.00M | 3 |
|
08 Mar 2022 |
| Seed Round | Unknown | 1 |
|
27 Jan 2021 |
| Grant | $269.96K | 1 |
|
13 Dec 2019 |
| Grant | $200.00K | 2 |
|
03 Sep 2019 |
No recent news or press coverage available for Mytide Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
